Business, energy, technology, markets and global industry news from Business News Today

Energenesis Biomedical

PharmaDeviceNews Energenesis Biomedical
Energenesis Biomedical and Taiwan Tanabe Seiyaku are advancing ENERGI-F703DFU, an investigational topical treatment for diabetic foot ulcers, through joint CMC and development work as the Phase III program progresses toward a potential Taiwan regulatory filing. Representative image.
Pharma & Biotech

Taiwan Tanabe joins CMC development for Energenesis diabetic foot ulcer drug ENERGI-F703DFU

Energenesis and Taiwan Tanabe advance ENERGI-F703DFU development as the Phase III diabetic foot ulcer program moves toward a Taiwan NDA.

Read More